AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Vaxcyte, Inc. Director's Dealing 2024

Jun 10, 2024

31100_dirs_2024-06-10_8932d8f1-33d1-445b-9205-e186d028c08e.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2024-06-07

Reporting Person: Eydelman Mikhail (SVP, GEN COUNSEL & CORP SEC)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-06-07	Common Stock	F	335	$70.97	Disposed	30826	Direct

Footnotes

F1: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of restricted stock units.